Mustang Bio (MBIO) Liabilities and Shareholders Equity (2016 - 2026)

Mustang Bio (MBIO) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $16.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 11.22% year-over-year to $16.6 million; the TTM figure through Mar 2026 stood at $66.6 million (up 66.75% YoY), while the FY2025 annual figure was $17.6 million, up 89.01% from the prior year.
• Liabilities and Shareholders Equity retreated to $16.6 million in Q1 2026 per MBIO's latest filing, from $17.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $137.0 million in Q1 2022 and bottomed at $7.2 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $42.5 million across 5 years, with a median of $17.7 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 81.1% — and 2025, when it jumped 169.16%.
• Mustang Bio's Liabilities and Shareholders Equity stood at $92.4 million in 2022, then tumbled by 80.8% to $17.7 million in 2023, then slumped by 47.54% to $9.3 million in 2024, then jumped by 89.01% to $17.6 million in 2025, then slipped by 5.75% to $16.6 million in 2026.
• Business Quant data shows MBIO's Liabilities and Shareholders Equity at $16.6 million in Q1 2026, $17.6 million in Q4 2025, and $19.4 million in Q3 2025.